Sharon Beesley Selected Research

Strontium-89

1/2017	Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
4/2016	Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
1/2016	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sharon Beesley Research Topics

Disease

4	Prostatic Neoplasms (Prostate Cancer) 01/2017 - 01/2016
1	Multiple Endocrine Neoplasia Type 2a (MEN 2) 03/2016
1	Pain (Aches) 01/2016
1	Seminoma 04/2009

Drug/Important Bio-Agent (IBA)

4	Zoledronic Acid (Zometa)FDA Link 01/2017 - 01/2016
3	Strontium-89IBA 01/2017 - 01/2016
3	Docetaxel (Taxotere)FDA Link 01/2017 - 03/2016
1	Hormones (Hormone)IBA 03/2016
1	Carboplatin (JM8)FDA LinkGeneric 04/2009

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2017 - 01/2016
2	Therapeutics 03/2016 - 01/2016
1	Castration 01/2016
1	Radiotherapy 04/2009